Universität zu Köln

Cheung, K. L., Evers, S. M. A. A., De Vries, H., Levy, P., Pokhrel, S., Jones, T., Danner, M., Wentlandt, J., Knufinke, L., Mayer, S. and Hiligsmann, M. (2018). Most important barriers and facilitators of HTA usage in decision-making in Europe. Expert Rev. Pharmacoecon. Outcomes Res., 18 (3). S. 297 - 305. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1744-8379

Full text not available from this repository.

Abstract

Background: To enhance usage of health technology assessment (HTA) in decision-making, it is important to prioritise important barriers and facilitators to the uptake of HTA. This study aims to quantify and compare the relative importance of barriers and facilitators regarding the use of HTA in several European countries.Methods: A survey containing two best-worst scaling (BWS) object case studies (i.e. barriers and facilitators) were conducted among 136 policy makers and HTA researchers from the Netherlands, Germany, France, and United Kingdom. Hierarchical Bayes analysis generated the mean relative importance score (RIS) for each factor and subgroup analyses assessed differences between countries.Results: Six barriers (RIS5) and five facilitators (RIS6) were deemed highly important. Eleven barriers and ten facilitators differed in their importance between countries. Policy characteristics, research & researcher characteristics, and organisation & resources were particularly important to facilitate uptake of HTA, such as an explicit framework for decision-making and research of sufficient quality.Conclusion: The most paramount barriers and facilitators to HTA usage were quantified. For all countries it is crucial to create an explicit framework for the decision-making context to include HTA evidence. Country differences in the quality of research emphasize the need for enhanced international collaboration in HTA.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Cheung, K. L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Evers, S. M. A. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED De Vries, H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Levy, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pokhrel, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Jones, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Danner, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wentlandt, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Knufinke, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mayer, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hiligsmann, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-200395
DOI:	10.1080/14737167.2018.1421459
Journal or Publication Title:	Expert Rev. Pharmacoecon. Outcomes Res.
Volume:	18
Number:	3
Page Range:	S. 297 - 305
Date:	2018
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1744-8379
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HEALTH TECHNOLOGY-ASSESSMENT; COST-EFFECTIVENESS ANALYSIS; ECONOMIC-EVALUATION; RESOURCE-ALLOCATION; CARE; WORST; ASSESSMENTS; COUNTRIES; IMPACT Multiple languages Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/20039